Primary Open-Angle Glaucoma (POAG) Market to Reach USD 10.3 Billion by 2034

Primary open-angle glaucoma (POAG) is the most common type of glaucoma, accounting for up to 70% of all glaucoma cases worldwide. It is characterized by progressive optic nerve damage and visual field loss, often associated with elevated intraocular pressure (IOP). Because the disease progresses silently, it is frequently diagnosed late, making it a leading cause of irreversible blindness globally.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72275

The POAG market is witnessing significant growth, fueled by rising prevalence of glaucoma in aging populations, advancements in minimally invasive glaucoma surgery (MIGS), and the adoption of long-acting drug delivery systems. Increasing integration of AI-powered screening and tele-ophthalmology is also helping improve early detection rates.

Market Overview
• Market Size (2024): USD 4.9 billion
• Forecast (2034): USD 10.3 billion
• CAGR (2025-2034): 7.6%

Key Highlights:
• Growing burden of glaucoma with rising global life expectancy.
• Increased adoption of sustained-release implants and long-acting drug delivery.
• Expanding role of MIGS and laser therapies in treatment.
• Strong demand for early screening and AI-driven diagnostic tools.

Segmentation Analysis
By Treatment Type:
• Medications
o Prostaglandin Analogs (first-line)
o Beta-Blockers
o Alpha-Agonists
o Carbonic Anhydrase Inhibitors
o Combination Drugs

• Laser Therapy
o Selective Laser Trabeculoplasty (SLT)
o Argon Laser Trabeculoplasty (ALT)

• Surgical Interventions
o Minimally Invasive Glaucoma Surgery (MIGS)
o Trabeculectomy
o Glaucoma Drainage Devices

• Sustained-Release Drug Delivery
o Implants (e.g., bimatoprost SR)
o Injectable Depot Formulations

By End Use:
• Hospitals & Specialty Eye Clinics
• Ambulatory Surgical Centers
• Retail & Online Pharmacies

Segmentation Summary:
Medications remain the backbone of POAG therapy, but the fastest-growing segments are MIGS and sustained-release implants, reducing reliance on daily eye drops.

Explore Full Report here: https://exactitudeconsultancy.com/reports/72275/primary-open-angle-glaucoma-poag-market

Regional Analysis
North America
• Largest market (~42% share in 2024).
• High prevalence of glaucoma and strong adoption of MIGS and implants.
• FDA approvals driving innovation in sustained-release therapies.
Europe
• ~30% share.
• Germany, UK, and France leading adoption of advanced glaucoma surgery.
• Increasing government initiatives for early screening programs.
Asia-Pacific
• Fastest-growing region, CAGR ~8.8%.
• Large patient pool, particularly in China, India, and Japan.
• Rising demand for affordable drugs and gradual uptake of surgical innovations.
Latin America
• Brazil and Mexico expanding glaucoma care infrastructure.
Middle East & Africa
• GCC countries advancing in MIGS adoption.
• Limited awareness and late diagnosis in most African countries.
Regional Summary:
North America and Europe lead in innovation and adoption, while Asia-Pacific shows the fastest growth potential, driven by its aging population and increasing healthcare investment.

Market Dynamics
Key Growth Drivers:
• Rising prevalence of aging populations and diabetes, both risk factors for POAG.
• Growing adoption of sustained-release and long-acting therapies.
• Expanding use of AI-powered diagnostics and tele-ophthalmology.
• Increasing awareness campaigns for glaucoma screening.

Key Challenges:
• Late diagnosis leading to irreversible vision loss.
• Poor patient compliance with daily eye drop regimens.
• High costs of MIGS and implants in emerging markets.
• Limited specialist availability in rural areas.

Latest Trends:
• Expansion of minimally invasive glaucoma surgery (MIGS).
• Development of gene therapy and neuroprotective drugs for optic nerve preservation.
• Integration of home-based IOP monitoring devices.
• Use of AI-based imaging (OCT, fundus cameras) for early detection.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72275

Competitor Analysis
Major Players in the Market:
• Novartis AG (Alcon - glaucoma portfolio)
• AbbVie Inc. (Allergan - Lumigan, Combigan)
• Santen Pharmaceutical Co., Ltd.
• Bausch + Lomb
• Johnson & Johnson Vision (MIGS devices)
• Iridex Corporation (laser systems)
• Glaukos Corporation (iStent, MIGS leader)
• Aerie Pharmaceuticals (now part of Alcon)
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.

Competitive Summary:
AbbVie and Novartis dominate the drug segment, while Glaukos and J&J Vision lead in MIGS devices. Bausch, Santen, and Alcon provide strong glaucoma drug portfolios, while biotech innovators are investing in neuroprotection and sustained-release therapies.

Conclusion
The Primary Open-Angle Glaucoma (POAG) Market, valued at USD 4.9 billion in 2024, is projected to reach USD 10.3 billion by 2034, growing at a CAGR of 7.6%.

Key Takeaways:
• Medications dominate today, but MIGS and long-acting implants are reshaping care.
• North America and Europe lead adoption, while Asia-Pacific grows fastest.
• AI diagnostics, sustained-release drug delivery, and gene therapy represent the future of POAG care.
• Improved compliance solutions and early screening programs will help reduce the global burden of glaucoma-related blindness.

Over the next decade, POAG management will evolve from short-term pressure control to integrated, long-acting, and potentially neuroprotective approaches, offering better long-term outcomes for millions of patients worldwide.

This report is also available in the following languages : Japanese (原発開放隅角緑内障(POAG)市場), Korean (원발성 개방각 녹내장(POAG) 시장), Chinese (原发性开角型青光眼(POAG)市场), French (Marché du glaucome primitif à angle ouvert (GPAO)), German (Markt für primäres Offenwinkelglaukom (POAG)), and Italian (Mercato del glaucoma primario ad angolo aperto (POAG)), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72275/primary-open-angle-glaucoma-poag-market#request-a-sample

Our More Reports:

Neuronal Ceroid Lipofuscinosis Market
https://exactitudeconsultancy.com/reports/72866/neuronal-ceroid-lipofuscinosis-market

Meibomian Gland Dysfunction Market
https://exactitudeconsultancy.com/reports/72867/meibomian-gland-dysfunction-market

Cholangiosarcoma Market
https://exactitudeconsultancy.com/reports/72868/cholangiosarcoma-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.